Backed by their common shareholder, Keensight Capital, one of the leading private equity funds dedicated to pan-European Growth Buyout investments, the combination of Biovian and 3P further extends the group’s value proposition to address complex customer needs across the entire development cycle.
The combined group, named 3PBIOVIAN, will offer unparalleled end-to-end development and manufacturing services for all protein expression systems and viral vectors, both for drug substance (DS) and drug product (DP), from preclinical to clinical development and commercial phases.
Leveraging a joint 40-year track record, expertise, capabilities,and financial strength, the group will position itself as a leading pan-European independent biologics CDMO, aiming to spearhead the development of drugs tackling patients’ unmet clinical needs.
"We are thrilled about this opportunity and the new chapter for our combined companies. The highly synergistic and comprehensive service offering allows 3PBIOVIAN to further enhance its competitiveness in the biologics CDMO market," said Antti Nieminen (pictured), Deputy CEO at 3PBIOVIAN.
"The combination of technology, capabilities and most importantly, the quality of the human team, positions us a leader in the highly dynamic international market for the development and manufacturing of advanced therapies," added Dámaso Molero Sánchez, CEO at 3PBIOVIAN.
